Wacker Chemie AG has acquired the production facilities and intellectual property of Bio Med Sciences, a US-based company. This acquisition diversifies Wacker's portfolio of medical products and expands its expertise and presence in the field of silicone-coated medical technology, strengthening its market presence in the US.
Bio Med Sciences, based in Allentown, Pennsylvania, specializes in developing and producing innovative silicone coatings and self-adhesive products for the healthcare industry. Founded in 1987, the company is renowned for its advanced solutions in wound care and scar treatment. Their products are designed to promote the healing of scars and wounds while ensuring patient comfort. Bio Med Sciences has built a reputation for offering products with optimal skin compatibility through their expertise in silicone technologies. They continuously introduce new technologies and products to meet the evolving demands of medical technology and improve patients' quality of life.
Wacker Chemie AG, headquartered in Munich, Germany, is a global chemical company founded in 1914. Wacker is a leading manufacturer in the chemical industry, offering a wide range of products and solutions used in construction, solar energy, electronics, and consumer goods. The company is a pioneer in silicone and polymer chemistry. With around 14,500 employees worldwide and production sites in Europe, America, and Asia, Wacker pursues a strategy of innovation and sustainability to meet customer needs in over 100 countries. The company’s mission is to enhance quality of life through chemical innovation while minimizing environmental impact.
Before acquiring Bio Med Sciences, Wacker already had significant expertise in silicone-coated products, particularly in medical technology and wound care. Key areas of expertise include:
Silicone Technology Expertise
Wacker has extensive experience in silicone production and processing, known for advanced silicone elastomers and fluids used in a variety of medical applications. These silicones offer excellent biocompatibility, skin-friendliness, and adaptability to medical requirements.
Medical Adhesives and Coatings
Wacker is a major supplier of silicone adhesives and coatings developed specifically for medical applications, including wound care, surgical dressings, and scar treatment. These adhesives are known for their skin-friendliness and strong adhesion without causing irritation or damage.
Product Development and Innovation
Wacker is renowned for continuous innovation in silicone technology, developing specialized products for a wide range of medical needs, including wearable devices and cosmetic applications. This innovation has made Wacker a preferred partner for high-quality silicone products.
Customer-Oriented Solutions
Wacker offers customized solutions tailored to the medical technology sector, providing comprehensive technical support and consulting services. This customer-centric approach has helped Wacker build close partnerships with leading medical device manufacturers.
The transaction includes a test and development center in Allentown, Pennsylvania, specializing in silicone coatings for medical devices and wound care. Most Bio Med Sciences employees will join Wacker Silicone Manufactured Innovations (WSMI), a wholly-owned subsidiary of Wacker.
With this acquisition, Wacker strengthens its position in the medical adhesives market and plans to use the acquired technologies as a platform for innovation, particularly in wearable medical devices and scar care products. The acquisition will enable Wacker to better support its customers with innovative adhesive solutions.
Financial terms were not disclosed, but the acquisition is expected to significantly expand Wacker’s market position by integrating new technology and expertise. Existing Bio Med Sciences consumer products and brands will remain with the original company and are not part of the acquisition.
This strategic move by Wacker demonstrates its commitment to expanding capabilities in medical silicone products and offering advanced solutions to customers.
ConAlliance is a leading independent investment banking and M&A advisory firm specializing in the global healthcare sector. Headquartered in Munich, with offices in London and other major cities worldwide, ConAlliance provides customized advisory services to the healthcare industry, focusing on mergers & acquisitions (M&A), corporate finance, and strategic advisory in medical technology, pharmaceuticals, biotechnology, diagnostics, and healthcare services.
Founded in 2011, ConAlliance has established itself as a trusted partner for companies in the healthcare sector. The team consists of experienced advisors and M&A professionals with in-depth expertise and an extensive network.
ConAlliance’s services include assistance with company sales and acquisitions, due diligence, valuations, post-deal integration, and capital raising. The firm is known for executing cross-border transactions, particularly between Europe, the USA, and Asia.
ConAlliance has completed over 150 transactions in the healthcare sector, known for a high success rate and client satisfaction. The firm provides sound financial and strategic advice, along with comprehensive healthcare and life sciences insight and analysis to create long-term value and achieve strategic objectives.
For more information, visit ConAlliance's official website.